Compare ATRC & SRPT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ATRC | SRPT |
|---|---|---|
| Founded | 2000 | 1980 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Medical/Dental Instruments | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.5B | 2.0B |
| IPO Year | 2005 | 2000 |
| Metric | ATRC | SRPT |
|---|---|---|
| Price | $57.29 | $17.45 |
| Analyst Decision | Buy | Hold |
| Analyst Count | 10 | 24 |
| Target Price | ★ $54.89 | $21.64 |
| AVG Volume (30 Days) | 1.4M | ★ 2.5M |
| Earning Date | 10-28-2026 | 11-02-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 74.74 | N/A |
| EPS | 0.18 | ★ 2.99 |
| Revenue | $201,630,000.00 | ★ $2,198,237,000.00 |
| Revenue This Year | $13.42 | N/A |
| Revenue Next Year | $12.12 | N/A |
| P/E Ratio | $307.50 | ★ $5.93 |
| Revenue Growth | 15.40 | ★ 15.58 |
| 52 Week Low | $25.36 | $14.68 |
| 52 Week High | $61.70 | $24.68 |
| Indicator | ATRC | SRPT |
|---|---|---|
| Relative Strength Index (RSI) | 58.35 | 39.98 |
| Support Level | $26.95 | $16.58 |
| Resistance Level | $61.70 | $18.16 |
| Average True Range (ATR) | 2.50 | 0.82 |
| MACD | -0.68 | -0.14 |
| Stochastic Oscillator | 55.81 | 10.06 |
AtriCure Inc is an innovator in surgical treatments and therapies for atrial fibrillation (Afib), left atrial appendage (LAA) management, and post-operative pain management, and sells its products to medical centers through its direct sales force and distributors. Its product line includes Cryo, Soft Tissue Dissection, RF Ablation, Pacing and Sensing, and others. Geographically, it generates a majority of its revenue from the United States. Cardiac ablation and left atrial appendage management (LAAM) products are used by physicians during open-heart and minimally invasive surgical procedures. Pain management solutions are used by physicians to freeze nerves during cardiothoracic or thoracic surgical procedures.
Sarepta Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the discovery and development of RNA-targeted therapies, gene therapies, and other genetic medicines for rare diseases, particularly neuromuscular disorders. The company has developed approved treatments for Duchenne muscular dystrophy, including EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS, and is advancing additional therapeutic candidates for neuromuscular and other rare diseases. The company operates in one segment: discovering, developing, manufacturing, and delivering therapies to patients with rare diseases.